Wednesday, 14 October 2026European Markets

PARETO BANK And CRCAM ALP.PROV.CCI Have A High Dividend Yield And Return On Equity In The Banks - Regional Industry.

Loading stream...

(vianews) - pareto bank (parb.ol) is among this list of stock assets with the highest dividend rate and return on equity on the banks - regional industry.

financial asset price forward dividend yield return on equity
pareto bank (parb.ol) kr55.40 7.02% 13.76%
crcam alp.prov.cci (crap.pa) €72.40 5.74% 3.99%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. pareto bank (parb.ol)

7.02% forward dividend yield and 13.76% return on equity

pareto bank asa provides various banking products and services in norway. the company accepts corporate deposits. it also offers corporate financing; receivables financing; residential and commercial financing for land and property; ship financing, including corporate and project financing; and other private or housing loans. pareto bank asa was incorporated in 2007 and is headquartered in oslo, norway.

earnings per share

as for profitability, pareto bank has a trailing twelve months eps of kr7.75.

pe ratio

pareto bank has a trailing twelve months price to earnings ratio of 7.15. meaning, the purchaser of the share is investing kr7.15 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.76%.

more news about pareto bank.

2. crcam alp.prov.cci (crap.pa)

5.74% forward dividend yield and 3.99% return on equity

caisse régionale de crédit agricole mutuel alpes provence société coopérative provides banking products and services in france. the company offers bank accounts; cards; e-documents; savings products; pension and employee savings products; real estate and consumer credit loans; cash management, business creation finance, medium term credit, and leasing services. it also provides life, health, employee, professional vehicle, activity, car and two-wheeler, personal, home, leisure and daily, borrowers, and professional premises insurance products. in addition, the company offers agriculture banking products and services. the company serves individuals, associations, professionals, businesses, farmers, and communities. caisse régionale de crédit agricole mutuel alpes provence société cooperative was founded in 1885 and is based in aix-en-provence, france. caisse régionale de crédit agricole mutuel alpes provence société coopérative operates as a subsidiary of crédit agricole s.a.

earnings per share

as for profitability, crcam alp.prov.cci has a trailing twelve months eps of €16.26.

pe ratio

crcam alp.prov.cci has a trailing twelve months price to earnings ratio of 4.45. meaning, the purchaser of the share is investing €4.45 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.99%.

revenue growth

year-on-year quarterly revenue growth declined by 12.7%, now sitting on 419.56m for the twelve trailing months.

dividend yield

as stated by morningstar, inc., the next dividend payment is on apr 25, 2023, the estimated forward annual dividend rate is 4.07 and the estimated forward annual dividend yield is 5.74%.

volume

today's last reported volume for crcam alp.prov.cci is 55 which is 69.27% below its average volume of 179.

moving average

crcam alp.prov.cci's worth is higher than its 50-day moving average of €70.56 and below its 200-day moving average of €76.57.

more news about crcam alp.prov.cci.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com